Egetis Therapeutics AB (publ)
SSE:EGTX.ST
6.07 (SEK) • At close February 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SEK.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities: | |||||||||||||||
| Net Income
| -343.6 | -326.9 | -193.8 | -104.542 | -179.12 | -61.422 | -85.003 | -87.935 | -38.223 | -43.836 | -48.42 | -25.549 | -33.857 | -33.246 | -3.801 |
| Depreciation & Amortization
| 0 | 3.6 | 2.7 | 2.455 | 0.395 | 0.21 | 0 | 0 | 0 | 0.002 | 0.002 | 0.002 | 0.004 | 17.096 | 0.002 |
| Deferred Income Tax
| 0 | 0 | 0 | -1.084 | 1.472 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation
| 0 | 8 | 8.8 | 1.2 | 0.557 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change In Working Capital
| 88.6 | 30.9 | 10.9 | -28.251 | 42.052 | -0.282 | 4.694 | 1.383 | 2.109 | -7.32 | 7.015 | -2.621 | 1.928 | 1.765 | 1.057 |
| Accounts Receivables
| 13.4 | -22.9 | -10.7 | 3.082 | 16.428 | 0.049 | -6.273 | -3.143 | -0.436 | 1.161 | -1.739 | -0.162 | -0.726 | 0 | 0 |
| Inventory
| 0 | 0 | 0 | 0 | 0 | 0.001 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables
| 0 | 53.8 | 21.6 | -31.333 | 25.624 | -3.968 | 9.201 | 1.294 | 2.912 | -8.201 | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital
| 75.2 | 0 | 21.6 | -31.3 | 25.624 | 3.636 | 1.765 | 3.234 | -0.367 | -0.279 | 0.064 | -1.406 | 0 | 0 | 0 |
| Other Non Cash Items
| 27.1 | 6 | -2.1 | 0.154 | 0.005 | -1.147 | -0.001 | 0.001 | -0.001 | 0.001 | 0.019 | 0.102 | -0.032 | -0.011 | 0.025 |
| Operating Cash Flow
| -227.9 | -278.4 | -173.5 | -130.11 | -134.639 | -62.641 | -80.31 | -86.551 | -36.115 | -51.153 | -41.384 | -28.066 | -31.957 | -14.396 | -2.717 |
| Investing Activities: | |||||||||||||||
| Investments In Property Plant And Equipment
| 0 | 0 | 0 | -0.172 | -0.024 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -9.413 | -2.245 |
| Acquisitions Net
| -1.2 | 0 | -1.7 | -5 | -59.52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Purchases Of Investments
| 0 | 0 | 0 | -0.785 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.05 | 0 | 0 |
| Sales Maturities Of Investments
| 0 | 0 | 0 | 5.8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activites
| 0 | -0.1 | 0 | -5.8 | 0.001 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.266 | 0 | 0 |
| Investing Cash Flow
| -1.2 | -0.1 | -1.7 | -5.957 | -59.543 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.216 | -9.413 | -2.245 |
| Financing Activities: | |||||||||||||||
| Debt Repayment
| -7.7 | 105.8 | -9.1 | -7.5 | 0 | -0.216 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued
| 301.5 | 381.9 | 177.4 | 0 | 250.75 | 91.258 | 0.655 | 2.083 | 405.555 | 1.21 | 95.839 | 18.56 | 0 | 115.814 | 0 |
| Common Stock Repurchased
| -1.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities
| -21.4 | -28.8 | 164.8 | -1.402 | -22.345 | -4.322 | 0 | 0 | -25.802 | 0 | -3.714 | 0 | 0 | -2.026 | 5.15 |
| Financing Cash Flow
| 270.9 | 458.9 | 155.7 | -8.902 | 228.405 | 86.72 | 0.655 | 2.083 | 379.753 | 1.21 | 92.125 | 18.56 | 0 | 113.788 | 5.15 |
| Other Information: | |||||||||||||||
| Effect Of Forex Changes On Cash
| 5.8 | -4.8 | 3.2 | 1.084 | -1.473 | 1.146 | 0.912 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Change In Cash
| 47.7 | 175.6 | -16.3 | -143.885 | 32.749 | 25.225 | -79.655 | -84.467 | 343.638 | -49.944 | 50.741 | -9.506 | -31.74 | 89.979 | 0.188 |
| Cash At End Of Period
| 351 | 303.3 | 127.7 | 143.965 | 287.85 | 255.101 | 229.876 | 309.531 | 393.998 | 50.36 | 100.043 | 49.302 | 58.808 | 90.548 | 0.568 |